Comprehensive decision-analytic model and bayesian value-of-information analysis: Pentoxifylline in the treatment of chronic venous leg ulcers

PharmacoEconomics

Volumn 24, Issue 5, 2006, Pages 465-478

  Iglesias, Cynthia P ^a   Claxton, Karl ^a,b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Department of Economics and Related Studies ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE;

BAYES THEOREM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; LEG ULCER; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BAYES THEOREM; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GREAT BRITAIN; HUMANS; MARKOV CHAINS; META-ANALYSIS; MIDDLE AGED; PENTOXIFYLLINE; PLACEBOS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; STATE MEDICINE; VARICOSE ULCER; VASODILATOR AGENTS;

EID: 33646819709     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624050-00005     Document Type: Review

References (30)

1. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18: 341-64
2. Stinnet AA, Mullay J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18: S68-80
3. Fleurence RL, Torgerson DJ. Setting priorities for research. Health Policy 2004; 69: 1-10
4. Claxton K, Sculpher M, Drummund M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002; 360: 711-5
5. Cooper NJ, Sutton AJ, Abrahms KR, et al. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. Health Econ 2000; 13: 203-26
6. Callam MJ, Ruckley CV, Harper DR, et al. Chronic ulceration of the leg: extent of the problem and provision of care. BMJ 1985; 290: 1855-6
7. Bosanquet N. Costs of venous ulcers: from maintenance therapy to investment programmes. Phlebology 1992; 1: 44-6
8. Brenner MA. Non healing venous stasis ulcers: pentoxifylline as adjunctive therapy. J Am Podiatr Med Assoc 1987; 77: 586-8
9. Jull AB, Waters J, Arrow B. Pentoxifylline for treatment of venous leg ulcers: systematic review. Lancet 2002; 359: 1551-4
10. Dale JJ, Ruckley CV, Harper DR, et al. Randomised, double blind placebo controlled trial of pentoxifylline in the treatment of venous leg ulcers. BMJ 1999; 319: 875-8
11. Schurmann W, Eberhardt R. The efficacy of pentoxifylline added to topical and compression therapy in patients with varicose and postthrombotic leg ulcers. Therapiewoche 1986; 36: 2343-5
12. Colgan MP, Dormandy J, Jones P, et al. Oxpentifylline treatment of venous ulcers of the leg. BMJ 1990; 300: 972-5
13. Falanga V, Fujitani RM, Diaz C, et al. Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 1999; 7: 208-13
14. Government Actuary's Department. Interim life tables 2003-based. 2004 [online]. Available from URL: http://www.gad.gov.uk/life_tables [Accessed 2005 May]
15. Franks PJ, Oldroyd MI, Dickson D, et al. Risk factors for leg ulcer recurrence: a randomized trial of two types of compression stocking. Age Ageing 1995; 24: 490-4
16. Morrell C, Liao XH, Cheater F, et al. The management of venous leg ulcers: a project to improve care. Nurs Stand 2001 Apr 11-17; 15 (30): 68-73
17. British National Formulary (September). British Medical Association/Royal Pharmaceutical Society of Great Britain. Vol. 40. London: BNF, 2004
18. Booth C. Review body for nursing staff, midwifes, health visitors and professions allied to medicine. London: HMSO, 2003 [online]. Available from URL: http://www.ome.uk.com/review.cfm?.body=6.20(Cm5716) [Accessed 2005 May]
19. HM Treasury. Appraisal and evaluation in central government: treasury guidance [online]. Available from URL: http://www.hm-treasury.gov.uk [Accessed 2005 May]
20. Spiegelhalter DJ, Thomas A, Best NG, et al. WinBUGS version 1.4 user manual. Cambridge: MRC Biostatistics Unit, 2002 [online]. Available from URL: www.mrc-bsu.cam.ac.uk/bugs [Accessed 2002 Apr]
21. Lambert PC, Sutton AJ, Burton PR, et al. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 2005 Aug 15; 24 (15): 2401-28
22. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester: John Wiley & Sons Ltd, 2004
23. Spiegelhalter DJ, Best NG. Bayesian methods for evidence synthesis and complex cost-effectiveness models: an example in hip prostheses. Stat Med 2003; 22: 3687-709
24. Gelman A, Carlin JB, Stern HS, et al. Bayesian data analysis. 2nd ed. Boca Raton (FL): Chapman & Hall/CRC, 2004
25. Iglesias CP, Nelson EA, Cullum NA, et al. VenUS: a randomised controlled trial of two bandages for treating venous leg ulcers. Health Technol Assess 2004; 8 (24): 41-8
26. Van Hout VA, Ai MJ, Gordon GS, et al. Cost, effects, and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309-19
27. Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Med Decis Making 2004; 24: 207-27
28. UK National Health Service Health Technology Assessment programme [online]. Available from URL: http://www.ncchta.org/ProjectData/ 3_project_record_published.asp?PjtId=1076&Searchtext=varicose+veins [Accessed 2005 May]
29. Belcaro G, Cesarone MR, Nicolaides AN, et al. Treatment of venous ulcers with pentoxifylline: a 6-month randomized double-blind, placebo controlled trial. Angiology 2002; 53: S45-7
30. De Sanctis MT, Belcaro G, Cesarone MR, et al. Treatment of venous ulcers with pentoxifylline: a 12-month double-blind, placebo controlled trial: microcirculation and healing. Angiology 2002; 53: S49-51